Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILACOR XR vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Angina pectoris due to coronary artery spasm (Prinzmetal's variant angina),Chronic stable angina,Essential hypertension
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
Intravenous: 500 mg every 6 hours.
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Extensively metabolized in the liver via CYP3A4; undergoes deacetylation and N-demethylation.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
98-99% bound to serum albumin and alpha-1-acid glycoprotein
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
1.1-1.8 L/kg (high Vd indicates extensive tissue binding)
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral: 40-50% (first-pass metabolism; food does not affect extent)
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
GFR 30-60 m L/min: initiate at 120 mg once daily, titrate cautiously; GFR <30 m L/min: not recommended due to risk of accumulation.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh Class A: initiate at 120 mg once daily; Child-Pugh Class B or C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and effectiveness in pediatric patients have not been established; no dosing recommendations.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Start at low end of dosing range (120 mg once daily) due to increased systemic exposure and risk of hypotension; titrate slowly.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None.
None
May cause hypotension, bradycardia, and heart block; avoid in patients with sick sinus syndrome or second- or third-degree AV block without a pacemaker; caution in patients with congestive heart failure; may increase risk of digitalis toxicity; abrupt withdrawal may worsen angina.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Sick sinus syndrome (except in presence of functioning ventricular pacemaker), second- or third-degree AV block (except with pacemaker), hypotension (systolic < 90 mm Hg), acute myocardial infarction with pulmonary congestion, hypersensitivity to diltiazem, concurrent use of ivabradine.
None
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase diltiazem plasma concentrations, leading to increased risk of adverse effects. Avoid high-fat meals as they may affect the absorption of the extended-release formulation.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
DILACOR XR (diltiazem) is a calcium channel blocker with limited human pregnancy data. In animal studies, at doses up to 5 times the maximum recommended human dose, no teratogenic effects were observed. However, embryofetal toxicity (increased fetal loss, growth retardation) occurred at maternally toxic doses. First trimester: No adequate human studies; risk cannot be excluded. Second and third trimesters: Use only if clearly needed; may cause maternal hypotension and reduced uteroplacental blood flow, potentially leading to fetal hypoxia and growth restriction. U. S. FDA Pregnancy Category C.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted in human breast milk. The milk-to-plasma (M/P) ratio ranges from 0.7 to 0.9. Limited data suggest infant exposure is low (approximately 1% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution advised; monitor infant for bradycardia, hypotension, and sedation. Alternative agents may be preferred.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Plasma volume and renal clearance increase during pregnancy, potentially reducing diltiazem concentrations. However, specific pharmacokinetic studies are lacking. Clinical response and blood pressure should guide dosing. Start at the lowest effective dose and titrate based on maternal heart rate and blood pressure. Avoid sustained-release formulations if rapid titration needed; immediate-release may be used. Monitor for hypotension, which may worsen uteroplacental perfusion. No specific dose adjustment recommended in published guidelines; use caution and individualized dosing.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
DILACOR XR is a sustained-release formulation of diltiazem, a calcium channel blocker. Do not crush or chew the capsule; swallowing whole is essential for extended-release properties. Monitor heart rate and blood pressure regularly due to risk of bradycardia and hypotension. Use with caution in patients with reduced hepatic function as diltiazem undergoes extensive first-pass metabolism. Avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) as they can increase diltiazem levels. In patients with atrial fibrillation or flutter, it may be used for rate control but contraindicated in sick sinus syndrome or second/third-degree AV block without a pacemaker.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Swallow DILACOR XR capsules whole; do not crush, chew, or break them.,Take this medication exactly as prescribed, usually once daily. Do not stop suddenly without consulting your doctor.,Avoid grapefruit and grapefruit juice as they can increase the effects and side effects of diltiazem.,Limit alcohol intake as it may increase the risk of dizziness or fainting.,Notify your doctor if you experience slow heartbeat, shortness of breath, swelling of ankles/feet, or severe dizziness.,Keep a record of your blood pressure and pulse at home and bring it to appointments.,Do not take other medications, including over-the-counter products or herbal supplements, without consulting your healthcare provider.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILACOR XR vs AMVAZ, answered by our medical review team.
DILACOR XR is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILACOR XR and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILACOR XR is: 180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILACOR XR and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILACOR XR is classified as Category C. DILACOR XR (diltiazem) is a calcium channel blocker with limited human pregnancy data. In animal studies, at doses up to 5 times the maximum recommended human dose, no teratogenic . AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.